Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results of Phase 3 Clinical Study of Riona® (ferric citrate hydrate) in Adult Patients with Iron Deficiency Anemia i...
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its collaboration partner, Japan Tobacco, Inc. (JT) and its subsidiary Torii Pharmaceutical Co., Ltd. (Torii), reported positive top-line results from a pivotal Phase 3 comparative study evaluating Riona® Tablets 250mg (generic name in Japan: ferric citrate hydrate) for the treatment of iron deficiency anemia (IDA) in adult patients in Japan. JT and Torii hold the exclusive rights to develop and commercialize Riona in Japan. Upon successful completion of its Phase 3 program, JT and Torii stated that they expect to file an application for approval of IDA as an additional indication for Riona in Japan.Riona was approved in Japan in 2014 as an oral treatment for the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD), including dialysis-dependent and non-dialysis dependent CKD. Ferric citrate is approved and marketed in the United States by Akebia under the tra
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia [Yahoo! Finance]Yahoo! Finance
- CNN values your feedback [CNN]CNN
- Thinking about buying stock in Ocugen, Akebia Therapeutics, Mind Medicine, SoundHound AI, or Canopy Growth?PR Newswire
- Stocks Set To Close Blowout Week, Month And Quarter At All-Time High; Gold Soars To Record [zero hedge]zero hedge
- Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis [Yahoo! Finance]Yahoo! Finance
AKBA
Earnings
- 3/14/24 - Beat
AKBA
Sec Filings
- 3/15/24 - Form 8-K
- 3/14/24 - Form 10-K
- 3/14/24 - Form 8-K
- AKBA's page on the SEC website